A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

NCT05273554 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Tumor
Adenocarcinoma

Interventions

DRUG: Pembrolizumab
DRUG: lenvatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]